Luo He Shi Hui Chuang Yi Yao You Xian Gong Si

The main purpose of the study is to study the pharmacokinetics of the test preparation benzbromarone tablets (specification: 50 mg, licensed by Luohe Huichuang Pharmaceutical Co., Ltd.) and the reference preparation benzbromarone tablets (Urinorm®, specification: 50 mg, licensed by Toeiyo Co., Ltd.) in healthy adult subjects after a single oral administration in the fasting and fed state, and to evaluate the bioequivalence of the two preparations in the fasting and fed state. The secondary purpose of the study is to evaluate the safety of the test preparation and reference preparation of benzbromarone tablets in healthy subjects after a single oral administration in the fasting and fed state.

Main research purpose: To study the single oral administration of the test preparation belatastin orally disintegrating tablets (specification: 10 mg, provided by Luohe Huichuang Pharmaceutical Co., Ltd.) and the reference preparation belatastin Pharmacokinetic behavior of orally disintegrating tablets (trade name: TALION®, strength: 10 mg, license holder: Mitsubishi Tambei Co., Ltd.) in healthy adult subjects, and evaluation of the oral administration of two formulations in fasting and postprandial states Bioequivalence. Secondary study objectives: To evaluate the fasting and postprandial oral administration of the test formulation (T) betaxylastine orally disintegrating tablets and the reference formulation (R) betaxylastine orally disintegrating tablets (TALION) in healthy subjects. ®) safety.